Once stiff-armed at the FDA, new management offers Amicus a warm embrace for Galafold -- priced at $315,000
It turns out the FDA wasn’t done Friday with the historic approval for Alnylam’s world’s-first RNAi drug. After the market close, Amicus Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
